Last updated: January 6, 2025
Sponsor: Tanta University
Overall Status: Completed
Phase
N/A
Condition
N/ATreatment
Bupivacaine
Dexmedetomidine
Ketamine
Clinical Study ID
NCT06331182
36264PR552/2/24
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Age ≥ 18 years.
Both sexes.
American Society of Anesthesiology (ASA) physical status I-III.
Scheduled for open thoracotomy.
Exclusion
Exclusion Criteria:
Patients with neurological or intellectual disability.
Infection at the injection site.
Opioid addiction.
Allergic reaction to local anesthetics.
Coagulation abnormalities.
Drug abuse.
Pregnancy.
Severe liver and/or renal failure.
Uncontrolled hypertension.
Severe cardiovascular problems.
Diabetes mellitus.
Study Design
Total Participants: 40
Treatment Group(s): 3
Primary Treatment: Bupivacaine
Phase:
Study Start date:
March 26, 2024
Estimated Completion Date:
November 01, 2024
Study Description
Connect with a study center
Tanta University
Tanta, ElGharbia 31527
EgyptSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.